JUN 23, 2020 3:24 PM PDT

Psychedelic DMT to Enter Clinical Trials

WRITTEN BY: Annie Lennon

Neuro-pharmaceutical company, MindMed, has announced that it will begin a double-blind placebo-controlled Phase 1 clinical trial to understand how N, N-Dimethyltryptamine (DMT), the primary psychoactive ingredient in Ayahuasca, works in the body. The company ultimately hopes to create therapeutics with the substance to treat mental health conditions like depression and addiction. 

“There is a growing trend in Western society to use Ayahuasca and DMT to facilitate a healing process for one’s mind. However, there is very limited safety data and clinical trials evaluating DMT as a potential medicine so we are going to double down on understanding the therapeutic opportunity and more effective ways to administer DMT in a controlled setting to achieve this healing process.” says JR Rahn, cofounder of MindMed. 

There are currently no approved clinical uses for DMT. The substance has nevertheless been used for centuries, if not longer, by various civilizations and tribes around the world for both its mentally restorative and explorative effects. In the first clinical trial of its kind, the researchers want to establish whether the substance could be engineered for future drug development programs to treat conditions like addiction. 

In partnership with the University Hospital Basel’s Liechti Lab, the researchers from MindMed thus plan to conduct experiments in which patients receive DMT intravenously. Quickly metabolized if taken orally, taking DMT intravenously means that the researchers will both be able to ensure continuous application of the substance, and thus a prolonged DMT experience.

It also means they will be able to stop administration of the substance and the ensuing DMT experience quickly should anything go wrong. In this way, the researchers hope to establish proper dosing during the trial with the goal of inducing a stable DMT experience of between an hour and two hours among patients. 

The study is expected to begin in late 2020, from which the researchers hope to lay the foundations for a future Phase II clinical proof of concept trials. 

 

Sources: MindMed, Bezinga

 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
MAY 11, 2020
Cancer
Using Deep Learning to Diagnose Breast Cancer Sub-Types
MAY 11, 2020
Using Deep Learning to Diagnose Breast Cancer Sub-Types
Cancer and computer programming may not sound like two things that go together. However, advanced programming techniques ...
MAY 21, 2020
Drug Discovery & Development
Molecular 'Switch' Makes Autoimmune Drugs Fight Cancer
MAY 21, 2020
Molecular 'Switch' Makes Autoimmune Drugs Fight Cancer
Researchers from the Antibody and Vaccine Group at the University of Southampton, England, have identified a way to repu ...
MAY 30, 2020
Cancer
Linking an Aggressive Tumor Factor to the Innate Immune Response
MAY 30, 2020
Linking an Aggressive Tumor Factor to the Innate Immune Response
Epithelial Ovarian Cancer (EOC) is a cancer of the fallopian tubes with a low five-year survival rate with a tendency to ...
JUN 16, 2020
Microbiology
A Bacterial Compound Could Become a Treatment for Parasitic Infections
JUN 16, 2020
A Bacterial Compound Could Become a Treatment for Parasitic Infections
The World Health Organization has estimated that parasitic infections cause over 48 million cases of illness and 59,000 ...
JUN 10, 2020
Drug Discovery & Development
A Highly Targeted Cancer Therapeutic
JUN 10, 2020
A Highly Targeted Cancer Therapeutic
A study led by researchers at USC School of Pharmacy discusses a way to engineer drugs that highly target malignant tiss ...
JUN 25, 2020
Drug Discovery & Development
Three New Molecular Targets for Epilepsy
JUN 25, 2020
Three New Molecular Targets for Epilepsy
A study lead by scientists at FutureNeuro discovered three new drugs hold the potential for targeting epilepsy. These dr ...
Loading Comments...